A052101
OPEN TO ACCRUAL
Ph 3 Study of Continuous v Intermittent Zanubrutinib Maintenance Therapy in Older Patients with MCL
S2114
OPEN TO ACCRUAL
Ph II Trial of Consolidation Tx Following CD19 CAR T Tx for Relapse/Refractory DLBCL or Gr IIIB FL
UW19086
OPEN TO ACCRUAL
LTFU Protocol for Subjects Treated with Gene-Modified T Cells
UW20062
OPEN TO ACCRUAL
Metabolic Profiling of Leukemic Cells through Isotope Tracing in Patients with CLL
UW22057
OPEN TO ACCRUAL
Single Arm Ph I/II Study of Tazemetostat with Rituximab and Abbrev Bendamustine in Tx of HTBFL
UW22069
OPEN TO ACCRUAL
PH 2 Study MK-2140 in pts with Aggressive and Indolent B-Cell Malignancies
UW22087
OPEN TO ACCRUAL
Phase II Study of Venetoclax-Obinutuzumab Retreatment in Patients with Recurring CLL
UW22157
OPEN TO ACCRUAL
Ph 1 Loncastuximab Tesirine Combo w DA-EPOCH-R in Pts w UnTx Aggress B-cell Lymphoid Malignancies
UW23106
OPEN TO ACCRUAL
Ph3 R open-label cmp efficacy of Glofitamab w POLA-R-CHP vs POLA-R-CHP in DLBCL
UW24107
OPEN TO ACCRUAL
Ph3 Study of Soquelitinib vs. Physician's Choice in Pts w/ R/R PTCL-NOS, FHTCL or sALCL